The Life Sciences team advised Elevara Medicines on the close of a $70 million Series A financing. The round was co-led by Forbion and Sofinnova Partners, with participation from founding investor, Monograph Capital. The Series A proceeds will fund Elevara's upcoming Phase 2 clinical trial of its lead candidate ELV001 and support exploratory programs in additional chronic inflammatory conditions and women's health.
Goodwin also advised Elevara on an agreement to gain the exclusive global rights to develop, commercialize and manufacture ELV001 from Teijin Pharma, part of the Teijin Group (TSE: 3401), which has dedicated over a decade of scientific work to the program to date.
Elevara is a clinical stage company developing new therapeutics to treat rheumatoid arthritis and other chronic inflammatory conditions. The Company's lead program, ELV001 is a potent, selective and well differentiated first-in-class oral CDK4/6 inhibitor which will be entering Phase 2 by the end of 2025. The ELV001 program is being positioned as an add-on oral therapy for RA patients with an incomplete response (IR) to a TNF inhibitor (TNFi), preventing cycling between multiple immunosuppressive therapies. The company was co-founded by Weatherden (a UK based clinical advisory group) and Monograph Capital. The Company raised $70m in a Series A in September 2025 and its investors are Sofinnova Partners, Forbion and Monograph Capital.
The Goodwin team deal for the investment was led by Andrew Harrow and Kesten Laverty. The licensing deal team was led by Morag Peberdy and Georgia Powell.
For more information on the deal, please read the press release.